To this end, we employed two human renal cell carcinoma cell lines, A-498 cells expressing wild-type p53 and 786-O cells harboring loss-of-function mutations in both p53 and the phosphatase and tensin homolog (PTEN) genes [18]. The gene discussed is PTEN; the disease is renal cell carcinoma.